Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

What have multicentre registries across the world taught us about the disease features of systemic sclerosis? (CROSBI ID 306168)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Proudman, Susanna M. ; Huq, Molla ; Stevens, Wendy ; Wilson, Michelle E. ; Sahhar, Joanne ; Baron, Murray ; Hudson, Marie ; Pope, Janet ; Allanore, Yannick ; Distler, Oliver et al. What have multicentre registries across the world taught us about the disease features of systemic sclerosis? // Journal of scleroderma and related disorders, 2 (2017), 3; 169-182. doi: 10.5301/jsrd.5000256

Podaci o odgovornosti

Proudman, Susanna M. ; Huq, Molla ; Stevens, Wendy ; Wilson, Michelle E. ; Sahhar, Joanne ; Baron, Murray ; Hudson, Marie ; Pope, Janet ; Allanore, Yannick ; Distler, Oliver ; Kowal-Bielecka, Otylia ; Matucci-Cerinic, Marco ; Low, Andrea H.L. ; Teng, Gim Gee ; Law, Weng Giap ; Santosa, Amelia ; Nikpour, Mandana ; Australian Scleroderma Interest Group (ASIG) ; Canadian Scleroderma Research Group (CSRG) ; EULAR Scleroderma Trials and Research group (EUSTAR) ; Singapore Scleroderma Workgroup (SCORE)

engleski

What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

Introduction The aim of this study is to compare the clinical features, mortality and causes of death of systemic sclerosis (SSc) patients in four large multicentre registries. Methods Patients seen at least once in the Australian Scleroderma Cohort Study (ASCS) (n = 1714), the Canadian Scleroderma Research Group (CSRG) (n = 1628), the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) Network (n = 13, 996) and the Systemic Sclerosis Cohort in Singapore (SCORE) (n = 500) before August 2016 were included. Clinical manifestations and survival in cohorts and disease subtypes were compared. Results Among 17, 838 SSc patients, most were female (86.1%), Caucasian (84.6%) and had the limited cutaneous subtype (lcSSc) (65.0%). The anti- centromere autoantibody was the most prevalent (37.6%). More patients in SCORE had the diffuse subtype (dcSSc) (49.3%) and Scl-70 autoantibody (38.8%) (p<0.001). Patients with dcSSc were more likely to be younger and male (p<0.001) and have shorter disease duration, more calcinosis, tendon friction rubs and synovitis (all p<0.001). Interstitial lung disease (ILD) occurred more frequently in dcSSc but prevalence of pulmonary arterial hypertension (PAH) was similar in both subtypes. More deaths occurred among SCORE patients who had the shortest median survival (p<0.001). The survival of patients with early disease, males and those with dcSSc was shorter than that of patients with prevalent disease, female gender and lcSSc, respectively. SSc-related complications accounted for more than 50% of deaths, with PAH and ILD being the most common. Conclusions This meta-cohort of SSc patients, the largest reported to date, provides insights into the impact of race and sex on disease manifestations and survival and confirms the early mortality in this disease.

Clinical features, Cohort study ; Multicentre registries ; Survival ; Systemic sclerosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

2 (3)

2017.

169-182

objavljeno

2397-1983

10.5301/jsrd.5000256

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost